An analysis of pooled data from two large finerenone trials identified key risk factors for hyperkalemia in patients with CKD ...

Vertex Pharmaceuticals Inc. closed 14.97% short of its 52-week high of $519.88, which the company achieved on November 8th.

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Vertex Pharmaceuticals's VRTX short percent of float has risen 27.71% since its last report. The company recently reported ...

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment -- and that’s set to continue thanks to the company's innovation. The company recently has expanded into another area ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

The stock's fall snapped a four-day winning streak.

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date. However, Vertex's shares plunged after ...

Eli Lilly's portfolio, both within and outside its core area, makes the stock attractive. However, a recent move Eli Lilly made reveals an underrated reason why the stock has attractive prospects.

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.